-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Eli Lilly and Company Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Revenue |
|
$24.54B | $28.32B | $28.54B | $34.12B |
| Cost of Revenue |
|
$5.48B | $7.31B | $6.63B | $7.08B |
| Gross Profit |
|
$19.06B | $21.01B | $21.91B | $27.04B |
| Research & Development |
|
$6.09B | $7.03B | $7.19B | $9.31B |
| Selling,General & Administrative |
|
$6.12B | $6.43B | $6.44B | $6.94B |
| Operating Expense |
|
$12.21B | $13.46B | $13.63B | $16.72B |
| Operating Income |
|
$6.06B | $6.36B | $7.13B | $10.33B |
| Net Income |
|
$6.19B | $5.58B | $6.24B | $5.24B |
Eli Lilly and Company Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$3.68B | $3.91B | $2.21B | $2.93B |
| Inventories |
|
$3.98B | $3.89B | $4.31B | $5.77B |
| Total Current Assets |
|
$17.46B | $18.45B | $18.03B | $25.73B |
| Property,Plant and Equipment |
|
$8.68B | $8.99B | $10.14B | $12.91B |
| Goodwill |
|
$3.77B | $3.89B | $4.07B | $4.94B |
| Total Assets |
|
$46.63B | $48.81B | $49.49B | $64.01B |
| Total Liabilities |
|
$40.81B | $39.65B | $38.71B | $53.14B |
| Retained Earnings |
|
$7.83B | $8.96B | $10.04B | $10.31B |
| Total Shareholder Equity |
|
$5.64B | $8.98B | $10.65B | $10.77B |
| Common Stock |
|
$598.20M | $596.30M | $594.10M | $593.60M |
Eli Lilly and Company Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$1.32B | $1.55B | $1.52B | $1.53B |
| Dividends Payout |
|
-$2.69B | -$3.09B | -$3.54B | -$4.07B |
| Capital Expenditures (Capex) |
|
-$2.03B | -$1.87B | -$2.48B | -$7.39B |
| Free Cash Flow (FCF) |
|
$4.47B | $5.39B | $4.60B | -$3.15B |
Eli Lilly and Company Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gross Profit |
|
$19.06B | $21.01B | $21.91B | $27.04B |
| Gross Profit Margin (%) |
|
77.66% | 74.18% | 76.77% | 79.25% |
| Operating Income |
|
$6.06B | $6.36B | $7.13B | $10.33B |
| Operating Income Margin (%) |
|
24.69% | 22.45% | 24.97% | 30.26% |
| Net Income |
|
$6.19B | $5.58B | $6.24B | $5.24B |
| Net Income Margin (%) |
|
25.24% | 19.71% | 21.88% | 15.36% |
| EBITDA |
|
$8.91B | $8.04B | $8.66B | $8.57B |
| EBITDA Margin (%) |
|
31.14% | 30.86% | 33.05% | 25.11% |
Eli Lilly and Company Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
109.79% | 62.16% | 58.64% | 48.65% |
| Return on Assets (ROA) |
|
13.28% | 11.44% | 12.62% | 8.19% |
| Debt to Equity |
|
294.16% | 188.04% | 152.48% | 234.18% |
| Debt to total asset |
|
35.59% | 34.60% | 32.81% | 39.41% |
| Enterprise value to revenue |
|
6.77 | 9.31 | 12.05 | 16.02 |
| Enterprise value to EBITDA |
|
18.64 | 32.77 | 39.73 | 63.81 |
| Enterprise value |
|
$166.18B | $263.59B | $344.06B | $546.67B |
| Cash to Debt |
|
39.17% | 43.00% | 43.63% | 16.81% |
| Tax Rate (%) |
|
14.33% | 9.32% | 8.25% | 20.05% |
| Payout Ratio |
|
43.38% | 55.30% | 56.62% | 77.65% |
